Experience of the Successful Treatment With Canakinumab of a Patient With Systemic Juvenile Idiopathic Arthritis
The article presents the follow-up of a patient with severe systemic juvenile idiopathic arthritis (JIA) resistant to glucocorticosteroids, to the first genetically engineered biologic drug (GEBD) tocilizumab, a monoclonal antibody to the interleukin (IL) 6 receptor. Switching to the second GEBD — a...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
"Paediatrician" Publishers LLC
2017-06-01
|
Series: | Voprosy Sovremennoj Pediatrii |
Subjects: | |
Online Access: | https://vsp.spr-journal.ru/jour/article/view/1749 |